8 studies found for:    BMS-663513
Show Display Options
Rank Status Study
1 Recruiting Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma or CLL
Condition: B-Cell Malignancies
Interventions: Biological: Urelumab;   Biological: Rituxan
2 Recruiting Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Condition: Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma
Intervention: Drug: Urelumab (BMS-663513)
3 Recruiting Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
Conditions: Colorectal Cancer;   Head and Neck Cancer
Interventions: Biological: Urelumab;   Biological: Cetuximab
4 Terminated A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC)
Condition: Non Small Cell Lung Cancer
Intervention: Drug: BMS-663513
5 Terminated A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies
Condition: Advanced Solid Malignancies
Intervention: Drug: BMS-663513
6 Terminated Study of BMS-663513 in Patients With Advanced Cancer
Condition: Tumors
Intervention: Drug: BMS-663513
7 Withdrawn Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma
Condition: Melanoma
Interventions: Drug: AntiCD137;   Drug: Ipilimumab
8 Completed Phase II, 2nd Line Melanoma - RAND Monotherapy
Condition: Melanoma
Intervention: Drug: Anti-CD137 (4-1BB) (BMS-663513)

Indicates status has not been verified in more than two years